Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.


TSX:MDP - Post by User

Comment by christophwaltzon Mar 24, 2021 10:33am
118 Views
Post# 32865915

RE:The drug Gleolan ...

RE:The drug Gleolan ...They stated in that article (https://www.cbc.ca/news/canada/nova-scotia/brain-surgery-halifax-advance-fighting-cancer-1.5920258) that there were 25-30 such surgeries done yearly "by the surgical group in Nova Scotia". I wonder if that's the entire province's surgies.

Populatin of Nova Scota is just shy of 1M at 970,000. Extraoplate that to all of Canada (37.5M) and that's 966 - 1159 surgeries per year.

x 3,000 = $2,898,000 to $3,479,381 revenue if they use it in every single one of those surgeries.

I've made quit a few assumptions in this calculation, so it's not gospel. It's not wild or anything but it would be a nice continued addition to revenue.
<< Previous
Bullboard Posts
Next >>